China Tacrolimus Market Research Report 2021-2025

0

DUBLIN, January 07, 2022–(BUSINESS WIRE)–The “Chinese Tacrolimus Market Investigation Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.

According to this market research, the sales value of tacrolimus in China has an upward trend from 2016 to 2020, with a CAGR of around 13.5% from 2016 to 2020. The sales revenue of tacrolimus in China was 1.57 billion yuan in 2020.

The growth rate in 2020 was 4.8% year on year, which slowed down from that of previous years due to the COVID-19 outbreak.

The analyst analyzes that as the epidemic situation has improved and hospitals resume their operations, the sales of Tacrolimus will experience a resumption of growth from 2021 to 2025. In addition, the sales will also increase due to the market expansion. Based on the research results, the rejection prevention indication in transplant operations generates the most sales for Tacrolimus.

However, the number of new dialysis patients each year far exceeds the number of organ transplant operations, which means that the demand for transplants is not being met. With the development of policies and the increase in the number of organ donations, more patients will be able to receive transplants in the future, which will increase the demand for tacrolimus.

Tacrolimus is a macrolide antibiotic and is also a new immunosuppressant. It is available in a variety of dosage forms. The ointment is used for moderate to severe atopic dermatitis where traditional therapies are not suitable, while the capsule and injection are used to prevent transplant rejection after liver or kidney transplant. In recent years, tacrolimus has become the first-line drug for liver and kidney transplantation. Tacrolimus eye drops are used in spring keratoconjunctivitis with poor anti-allergic treatment.

The original tacrolimus drug was developed by Fujisawa Pharmaceutical, which became Astellas after the merger. Tacrolimus was launched in China in 2005. In addition to Astellas, other manufacturers in the Chinese tacrolimus market include Hangzhou Zhongmeihuadong, LEO, Zhejiang Hisun, and Sinopharm Chuankang.

Topics Covered:

  • The impact of COVID-19 on the Chinese tacrolimus market

  • China Tacrolimus Sales Value and Volume 2016-2020

  • Competitive Landscape of Chinese Tacrolimus Market

  • tacrolimus price in china

  • Tacrolimus Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese tacrolimus market

  • China tacrolimus market outlook from 2021 to 2025

Main topics covered:

1 Relevant concepts of tacrolimus

1.1 Indications for tacrolimus

1.2 Tacrolimus Development in China

1.3 Government approval of tacrolimus in China

1.4 The impact of COVID-19 on tacrolimus sales in China

2 China Tacrolimus Sales, 2016-2020

2.1 Tacrolimus Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Tacrolimus Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 China Tacrolimus Sales by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Eye drops

2.3.3 Capsule

2.3.4 Ointment (cream)

3 Analysis of Tacrolimus Key Manufacturers in China, 2016-2020

3.1 Tacrolimus Key Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Astellas Pharma Co Ltd

3.2.1 Company profile

3.2.2 PROGRAF (Astellas Tacrolimus) Sales in China

3.3 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.

3.3.1 Company Profile

3.3.2 China Saifukai (Hangzhou Zhongmeihuadong Tacrolimus) Sales

3.4 LEO Pharma A/S

3.4.1 Company Profile

3.4.2 PROTOPIC (LEO’s Tacrolimus) Sales in China

3.5 Zhejiang Hisun Pharmaceutical Co., Ltd.

3.5.1 Business Profile

3.5.2 China Fumeixin (Zhejiang Hisun Tacrolimus) Sales

3.6 Sinopharm Chuankang Pharmaceutical Co., Ltd.

3.6.1 Company Profile

3.6.2 China Yilikang (Sinopharm Chuankang Tacrolimus) Sales

4 tacrolimus prices for different manufacturers in China, 2020-2021

4.1 Astellas Pharma Co Ltd (PROGRAF)

4.2 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (Saifukai)

4.3 LEO Pharma A/S (PROTOPIC)

4.4 Zhejiang Hisun Pharmaceutical Co., Ltd. (Fumeixin)

4.5 Sinopharm Chuankang Pharmaceutical Co., Ltd. (Yilikang)

5 China Tacrolimus Market Outlook, 2021-2025

5.1 Influencing Factors of China Tacrolimus Market Development

5.1.1 The impact of COVID-19 on the Chinese tacrolimus market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

For more information on this report, visit https://www.researchandmarkets.com/r/hwa65n

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220107005234/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
[email protected]
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900

Share.

Comments are closed.